Are US patients really subsidising healthcare in Switzerland?

US President Donald Trump says US patients are subsidising healthcare in the rest of the world. Is this true? Swissinfo took a look at the facts.

This content was published on

September 4, 2025 – 10:18

Jessica Davis Plüss

I report on the Swiss pharmaceutical industry and healthcare topics such as access to medicine, biomedical innovation, and the impact of diseases like cancer.
I grew up just outside San Francisco and studied international affairs with a focus on development economics and healthcare policy. Prior to joining SWI swissinfo.ch in 2018, I was a freelance journalist and a researcher on business and human rights.

Isabelle Bannerman

My work focuses on engaging with you, our audience, and strengthening trust in our journalism. I develop engagement tools such as multilingual debates and help distribute our content to users across platforms.
A former nurse, I later pursued English linguistics and media studies where I developed a keen interest in journalism and news in the digital age.

US President Donald Trump argues US patients pay high prices for medicine so pharmaceutical companies can invest in new treatments that benefit the whole world. As Trump sees it, US patients are subsidising healthcare in other countries.

There is some truth to this.

Are US drug prices really that high?

The US makes up just 4.2% of the world’s population but delivers 40% to 60% of total revenue for big pharma companies – including Swiss companies Roche and Novartis. Last year, just over half of Roche’s global pharmaceutical revenue (CHF46 billion, $57 billion) came from the US.

This is because companies sell more medicine in the US and charge more. Multiple studies, including this oneExternal link from the Rand corporation, an American think tank, show prices of brand-name prescription drugs are two to three times more in the US than in Europe.

However, Switzerland still has some of the highest drug prices and per capita healthcare costs in Europe.

Why are US drug prices so high?

Unlike in Switzerland or most of Europe, there are no government price controls or a central price negotiator. The Inflation Reduction Act, enacted in 2022, authorised the US government to negotiate directly with drug companies on some drugs for the state-run insurance scheme for seniors (Medicare). But this is only for a small set of drugs and patients.

In May, Trump announced the “most-favoured nation” executiveExternal link order, which intends to tie US drug prices to those paid by other developed countries. This would bring down drug prices in the US by 60% to 90%, according to Trump. He also called on European governments to raise prices to make up for any loss in revenue.

He restated his demands this summer. Trump sent letters to 17 major pharmaceutical companies calling for immediate measures to lower drug prices in the US.

Medicine access

Despite Trump’s bold claims, medicine prices in Europe won’t rise anytime soon

This content was published on

May 15, 2025

US President Trump has taken aim at Europe for undercharging for medicine. But raising prices in Europe would face strong pushback.

What happens if prices drop in the US?

The ten largest pharmaceutical companies spend around 20% of their global revenue on new treatments. If prices drop in the US (and nothing else changes) companies will have less revenue, which could lead to less investment in new medicine.

But there remains a big question: how much profit companies make on high US prices.

Edited by Veronica DeVore/Virginie Mangin/ts

What’s your experience with rising costs for healthcare and medicine?

What do you think should be done to make medicine more accessible? How has this impacted you?

View the discussion

Articles in this story

Series Truth or tale

How have medicine shortages impacted your healthcare experience?

How have medicine shortages impacted you? What should be done about them?

View the discussion

Pharmaceutical companies do not plan job cuts in Switzerland

US tariffs: pharma firms not planning job cuts in Switzerland

This content was published on

Aug 10, 2025

The additional investments in the US will not lead to a reduction in jobs in Switzerland. This is according to pharmaceutical giant Roche, which expects the number of employees to remain stable in the current year. The position of Novartis is similar.